Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Jarlier

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
Pediatric Pulmonology. Supplement|January 1, 1997
Tuberculosis: new tools for diagnosisV Jarlier
Bulletin De L'Academie Nationale De Medecine|December 19, 2022
[Discussion about the presentation: "Impact of the first year of the COVID-19 pandemic on the epidemiology of invasive infections (bacteremia) in the hospitals of the Assistance publique-hôpitaux de Paris"]V Jarlier
Presse Medicale (Paris, France : 1983)|November 3, 1998
[Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor]V Jarlier
The Journal of Antimicrobial Chemotherapy|October 29, 2000
Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamasesW Sougakoff, V Jarlier
Pathologie-Biologie|October 14, 1998
[Surveillance of multiresistant bacteria: justification, role of the laboratory, indicators, and recent French data]L Marty, V Jarlier
Journal of Bacteriology|March 1, 1990
Permeability barrier to hydrophilic solutes in Mycobacterium cheloneiV Jarlier, H Nikaido
Revue Des Maladies Respiratoires|December 29, 2004
[New diagnostic tools for tuberculosis: the revolution is not over]N Veziris, V Jarlier
Research in Microbiology|January 1, 1996
Resistance to quinolones in mycobacteriaE Cambau, V Jarlier
Presse Medicale (Paris, France : 1983)|September 1, 1990
[Serum pharmacokinetics and in vitro antibacterial activity of pefloxacin, ofloxacin and ciprofloxacin]P Nordmann, V Jarlier
Revue Des Maladies Respiratoires|June 6, 2007
[Multi-resistant tuberculosis in France]J Robert, V Jarlier
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
Pediatric Pulmonology. Supplement|January 1, 1997
Tuberculosis: new tools for diagnosisV Jarlier
Bulletin De L'Academie Nationale De Medecine|December 19, 2022
[Discussion about the presentation: "Impact of the first year of the COVID-19 pandemic on the epidemiology of invasive infections (bacteremia) in the hospitals of the Assistance publique-hôpitaux de Paris"]V Jarlier
Presse Medicale (Paris, France : 1983)|November 3, 1998
[Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor]V Jarlier
The Journal of Antimicrobial Chemotherapy|October 29, 2000
Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamasesW Sougakoff, V Jarlier
Pathologie-Biologie|October 14, 1998
[Surveillance of multiresistant bacteria: justification, role of the laboratory, indicators, and recent French data]L Marty, V Jarlier
Journal of Bacteriology|March 1, 1990
Permeability barrier to hydrophilic solutes in Mycobacterium cheloneiV Jarlier, H Nikaido
Revue Des Maladies Respiratoires|December 29, 2004
[New diagnostic tools for tuberculosis: the revolution is not over]N Veziris, V Jarlier
Research in Microbiology|January 1, 1996
Resistance to quinolones in mycobacteriaE Cambau, V Jarlier
Presse Medicale (Paris, France : 1983)|September 1, 1990
[Serum pharmacokinetics and in vitro antibacterial activity of pefloxacin, ofloxacin and ciprofloxacin]P Nordmann, V Jarlier
Revue Des Maladies Respiratoires|June 6, 2007
[Multi-resistant tuberculosis in France]J Robert, V Jarlier
Pageof 18